Semaglutide represents the superior choice for patients seeking maximum weight loss efficacy and who can tolerate gastrointestinal side effects during the initial months of treatment
In addition, it is necessary to measure, assess and manage CV risk factors aggressively
The findings of these studies combined clearly suggests that early management with GLP-1 receptor agonists may successfully prevent the development from simple steatosis to more serious liver disease
Others are beginning to offer compounded versions of an older GLP-1 drug called liraglutide that needs to be injected daily instead of weekly and causes more side effects, but it is a GLP-1 agonist
Compounded oral drops have no reliable head-to-head data proving equivalent weight-loss outcomes to the branded injectables
Overweight and obesity are associated with increased risk of infertility including an increased time to pregnancy, ovulatory dysfunction, and when using assisted reproductive technology, a lower chance of pregnancy success (Van Der Steeg et al
